News
17 March 2020
Cambridge Cognition wins £1.37m of new eCOA contracts
The Company is pleased to announce that it has won a contract for three phase II studies with a new pharmaceutical client - providing CANTABTM cognitive assessments and eCOA services.
Read on
17 March 2020
Cambridge Cognition: COVID-19 Update
We would like to update you on the steps Cambridge Cognition is taking to ensure business continuity for all our customers as the widespread impact of COVID-19 (coronavirus) continues to affect so many globally.
Read on
25 November 2019
Cambridge Cognition expands eCOA offering and wins contract with top 10 pharmaceutical company
Cambridge Cognition is pleased to announce the launch of an improved electronic clinical outcomes assessment (eCOA) platform that has already attracted a new client from one of the world's top 10 pharmaceutical companies.
Read on
25 October 2019
Renewed promise for early Alzheimer’s drug signals potential for Cambridge Cognition’s assessment so
Following a consultation with the U.S. Food and Drug Administration (FDA), Biogen and Eisai have announced plans to pursue regulatory approval for aducanumab, which would be the first therapy to tackle clinical decline in early Alzheimer's disease. If successful, this presents an opportunity for Cambridge Cognition whose CANTABTM assessments are specifically sensitive to the early cognitive decline during Alzheimer's disease.
Read on
14 August 2019
Dr. Nick Kerton
Cambridge Cognition Holdings is deeply saddened to report the death of Nick Kerton, the Company’s former Chief Executive Officer and Non-executive Director, after a long fight with cancer.
Read on
12 August 2019
Cambridge Cognition expands further into Chinese market and initial university contract
Cambridge Cognition is pleased to announce its expansion into the Chinese market with the Company’s Cambridge Neuropsychological Test Automated Battery (“CANTAB”) computerised assessments. This move strengthens the Company’s global position, having announced a major opportunity in India earlier this year.
Read on
19 July 2019
New Commercial Partnership and Further Scientific Validation for NeuroVocalix
Cambridge Cognition is pleased to announce the second commercial partnership with a leading pharmaceutical company, for its NeuroVocalixTM platform. NeuroVocalixTM is a unique voice biomarker technology and the product was launched last year and recently presented ground-breaking demonstrable evidence of the potential at a major global Alzheimer’s conference.
